
    
      Efficacy and safety evaluation of IBI308 versus paclitaxel/irinotecan in patients with
      advanced/metastatic esophageal squamous cell carcinoma after failure of first-line treatment:
      a randomized, open-label, multicenter, phase 2 study (ORIENT-2)
    
  